We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Emisphere Announces Multi-Product Research Collaboration Agreement with Roche

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Emisphere Technologies, Inc. has announced that it has entered into a multi-product research collaboration agreement with Roche to explore the use of Emisphere's eligen® technology in feasibility studies for oral formulations of a number of Roche molecules.

Roche will fund the research, which will be conducted at both Roche and Emisphere.

Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, Emisphere Technologies, Inc., commented, "Establishing a research collaboration agreement with Roche to investigate the application of our technology on multiple compounds demonstrates the value Emisphere brings to the product development process."

"Roche has been working with Emisphere for a number of years and this new agreement further strengthens the relationship between our two companies."